Novadaq Technologies Inc.

Novadaq Technologies Inc.

January 28, 2008 07:00 ET

Novadaq Data Presented at 2008 Society of Thoracic Surgeons Meeting

Novadaq's SPY and PINPOINT Imaging Systems Featured in Key Presentations

TORONTO, ONTARIO--(Marketwire - Jan. 28, 2008) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time medical imaging
systems and image guided therapies for the operating room, today announced that
independent data on SPY® and PINPOINT™ was presented at an educational
program for cardiothoracic surgeons. The event, co-hosted with four other medical
device companies, took place during the 44th Annual Society of Thoracic Surgery
(STS) meeting which was held January 26th - January 30th, 2008 in Fort
Lauderdale, Florida. The STS represents the largest gathering of cardiothoracic
surgeons in the world and is considered the premiere global meeting.

The invitation-only event included comprehensive presentations and open
discussions by cardiac and thoracic surgeons highlighting the latest medical
therapies and technologies. Novadaq's products, the SPY Intra-operative
Imaging System and the PINPOINT Autofluorescence Endoscopic Imaging System,
were featured in two of the five key presentations:

- Autofluorescence Brochoscopy and Photodynamic Therapy: A Thoracic
Surgeon's Perspective by Patrick Ross Jr., M.D., Ph.D., Associate
Professor and Director of Thoracic Surgery at Ohio State University
and Director of Thoracic Oncology at the Arthur G. James Cancer
Hospital in Columbus, Ohio

- SPY Intra-Operative Imaging in Graft Assessment by David Paul
Taggart, M.D., Ph.D., FRCS, Professor of Cardiovascular Surgery for
the John Radcliffe Hospital in Oxford, UK

Dr. Patrick Ross stressed the clinical importance of using
autofluorescence imaging to provide guidance during endoluminal and
traditional surgical treatments for lung cancer. Dr. Ross reported the use of
real-time autofluorescence bronchoscopy, compared to the gold standard white
light bronchoscopy, provides for a more detailed assessment of the patient's
anatomy before pulmonary resection, a more accurate assessment for the
presence of early lung cancers and the ability to more precisely perform
endoluminal therapies such as Photodynamic Therapy. Dr. Ross also reminded the
cardiothoracic surgeon audience that autofluorescence bronchoscopy is now
recommended in the 2008 American College of Chest Physicians Evidence Based
Practice Guidelines for use in detecting cancerous lesions and for guiding
surgical treatments in patients with lung cancer.

Professor Taggart reported his clinical experience using the SPY
Intra-operative Imaging System to optimize the clinical outcomes of his
coronary artery bypass procedures, which have been previously published in the
literature and confirm the need for intra-operative graft assessment.
Professor Taggart's presented clinical results of studies he has performed
using SPY. Data reported by others indicating that as many as 30% of all vein
grafts may be closed at 1 year post bypass were also included. Professor
Taggart stressed that coronary artery disease has become more complex, making
coronary artery bypass surgery more technically demanding, which further
increases the need for real-time assessment of graft quality. Professor
Taggart reported on studies of the clinical utility of available technologies
for graft assessment, including a report by Nimesh Desai, MD.,,
published in The Journal of Thoracic and Cardiovascular Surgery in 2006. The
randomized study compared SPY and the Transit Time Flow Meter, the two most
commonly used tools, to the gold standard x-ray angiography. In the study of
139 bypass grafts, SPY was found to result in 83% sensitivity and 100%
specificity compared to 25% and 94% respectively for the Transit Time Flow

"Our presence at STS 2008 represents the progress our company has made
over the past 12 months. Last year at STS we had only our SPY System to offer
and we had just hired our first few direct sales representatives," said Dr.
Arun Menawat, President and Chief Executive Officer of Novadaq Technologies
Inc. "Today we have expanded our offerings to include the Heart Laser™
System for TMR and our PINPOINT Endoscopic Imaging System and have a fully
engaged sales organization covering the entire US. The feedback from our
surgeon customers like Drs. Ross and Taggart continues to confirm that our
products contribute to the overall technical success of their procedures and
that image guidance ultimately does facilitate optimal treatment strategies
and improve clinical outcomes for patients."

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging systems and real-time image guided therapies for use in the operating
room. Novadaq's proprietary ICG imaging systems can be used to visualize blood
vessels, nerves and the lymphatic system during a variety of surgical
procedures. Novadaq's SPY Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of heart bypass surgery. The SPY System
is expandable to include upgrade kits for use during other surgeries such as
other cardiovascular, plastic, reconstructive and organ transplant surgery
allowing surgeons to evaluate blood flow and tissue and organ perfusion. In
addition, SPY is ideal for use during urological procedures enabling surgeons
to visualize vessels, tumors, the lymphatic system and potentially nerve
bundles. Novadaq's OPTTX® System is aimed at the diagnosis, evaluation and
treatment of wet Age-related Macular Degeneration (AMD) by using the same core
imaging technology that is used in the SPY Imaging System. Novadaq also offers
the FDA approved PINPOINT endoscopic system for visualizing native tissue
fluorescence which allows surgeons to differentiate between healthy and
cancerous tissue in the lung during thoracic surgery. Novadaq is also the
exclusive United States distributor of PLC Medical's CO2 HEART LASER™
System for TMR (Trans-Myocardial Revascularization). For more information,
please visit the company's website at

Forward looking Statements

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, results of future
clinical tests of PINPOINT and the SPY System, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at

Contact Information